Your browser doesn't support javascript.
Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
Guo, Bao-Qiang; Li, Hong-Bin; Yang, Li-Qiang.
  • Guo BQ; School of Public Health, Xinxiang Medical University, Xinxiang, Henan 453003, China. Electronic address: guoxxmu@126.com.
  • Li HB; School of Public Health, Xinxiang Medical University, Xinxiang, Henan 453003, China.
  • Yang LQ; School of Public Health, Xinxiang Medical University, Xinxiang, Henan 453003, China.
Vaccine ; 41(28): 4067-4080, 2023 06 23.
Article in English | MEDLINE | ID: covidwho-2323413
ABSTRACT

BACKGROUND:

The incidence of myopericarditis after mRNA COVID-19 vaccination among adolescents aged 12-17 years remains unknown. Therefore, we conducted a study to pool the incidence of myopericarditis following COVID-19 vaccination in this age group.

METHODS:

We did a meta-analysis by searching 4 electronic databases until February 6, 2023. The following main keywords were used "COVID-19", "vaccines", "myocarditis", "pericarditis", and "myopericarditis". Observational studies reporting on adolescents aged 12-17 years who had myopericarditis in temporal relation to receiving mRNA COVID-19 vaccines were included. The pooled incidence of myopericarditis and 95 % confidence interval (CI) were calculated using a single-group meta-analysis.

RESULTS:

Fifteen studies were included. The pooled incidences of myopericarditis after mRNA COVID-19 vaccination among adolescents aged 12-17 years were 43.5 (95 % CI, 30.8-61.6) cases per million vaccine doses for both BNT162b2 and mRNA-1273 (39 628 242 doses; 14 studies), and 41.8 (29.4-59.4) cases for BNT162b2 alone (38 756 553 doses; 13 studies). Myopericarditis was more common among males (66.0 [40.5-107.7] cases) than females (10.1 [6.0-17.0] cases) and among those receiving the second dose (60.4 [37.6-96.9] cases) than those receiving the first dose (16.6 [8.7-31.9] cases). The incidences of myopericarditis did not differ significantly when grouped by age, type of myopericarditis, country, and World Health Organization region. None of the incidences of myopericarditis pooled in the current study were higher than those after smallpox vaccinations and non-COVID-19 vaccinations, and all of them were significantly lower than those in adolescents aged 12-17 years after COVID-19 infection.

CONCLUSIONS:

The incidences of myopericarditis after mRNA COVID-19 vaccination among adolescents aged 12-17 years were very rare; they were not higher than other important reference incidences. These findings provide an important context for health policy makers and parents with vaccination hesitancy to weight the risks and benefits of mRNA COVID-19 vaccination among adolescents aged 12-17 years.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Myocarditis Type of study: Observational study / Prognostic study / Reviews Topics: Vaccines Limits: Adolescent / Adult / Female / Humans / Male / Young adult Language: English Journal: Vaccine Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Myocarditis Type of study: Observational study / Prognostic study / Reviews Topics: Vaccines Limits: Adolescent / Adult / Female / Humans / Male / Young adult Language: English Journal: Vaccine Year: 2023 Document Type: Article